Treatment of Hereditary Hemorrhagic Telangiectasia-Related Epistaxis
| Autor: | Timothy L. Smith, Nathan B. Sautter |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Bevacizumab Severity of Illness Index Hemostatics 03 medical and health sciences 0302 clinical medicine Severity of illness otorhinolaryngologic diseases medicine Multiple treatments Secondary Prevention Humans 030223 otorhinolaryngology Telangiectasia medicine.diagnostic_test business.industry Hemostatic Techniques Incidence (epidemiology) Autosomal dominant trait Endoscopy General Medicine Dermatology Combined Modality Therapy Hemostasis Surgical Surgery Epistaxis Outcome and Process Assessment Health Care Otorhinolaryngology 030220 oncology & carcinogenesis Telangiectasia Hereditary Hemorrhagic medicine.symptom business medicine.drug |
| Zdroj: | Otolaryngologic clinics of North America. 49(3) |
| ISSN: | 1557-8259 |
| Popis: | Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an incidence of 1:5000. Recurrent, spontaneous epistaxis is the most common presenting symptom. Severity of epistaxis varies widely, from mild, self-limited nosebleeds to severe, life-threatening nasal hemorrhage. Treatment of HHT-related epistaxis presents a challenge to the otolaryngologist due to the recurrent, persistent nature of epistaxis often requiring multiple treatments. Treatment modalities range from conservative topical therapies to more aggressive surgical treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|